-
公开(公告)号：US08048898B2
公开(公告)日：2011-11-01
申请号：US12671401
申请日：2008-08-01
IPC分类号： C07D413/14 , C07D413/12 , C07D401/14 , C07D401/12 , C07D213/70 , C07D213/68 , C07D213/643 , A61K31/5377 , A61K31/496 , A61K31/4725 , A61K31/4709 , A61K31/4439 , A61K31/4436 , A61K31/443 , A61K31/44
CPC分类号： C07D213/64 , C07D213/68 , C07D213/70 , C07D213/71 , C07D239/34 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y1 is CRA, Y2 is CRB and Y3 is CRC), X represents an oxygen atom, etc., R1 represents a C1-C6 alkyl group, etc., R2 represents a C1-C6 alkyl group, etc., R3 represents an optionally substituted phenyl group, etc., R4 represents a hydrogen atom, etc., and R5 represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.
摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐：（其中Y1表示氮原子或由CRA表示的基团，Y2表示氮原子或由CRB表示的基团，Y3表示氮原子或表示 通过CRC，RA，RB和RC可以相同或不同，各自表示氢原子等（不包括Y1为CRA，Y2为CRB且Y3为CRC的情况），X为氧原子等 R1表示C1-C6烷基等，R2表示C1-C6烷基等，R3表示可以具有取代基的苯基等，R4表示氢原子等，R5表示 任选取代的苯基等）对S1P与其受体Edg-1（S1P1）之间的结合具有抑制作用，并且可用作自身免疫性疾病，类风湿性关节炎，哮喘，特应性皮炎，器官移植后的排斥反应的治疗剂 ，癌症，视网膜病变，牛皮癣，骨关节炎或年龄相关 黄斑变性等
-
公开(公告)号：US20100234594A1
公开(公告)日：2010-09-16
申请号：US12671401
申请日：2008-08-01
IPC分类号： C07D413/12 , C07D239/34 , C07D401/12
CPC分类号： C07D213/64 , C07D213/68 , C07D213/70 , C07D213/71 , C07D239/34 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y1 is CRA, Y2 is CRB and Y3 is CRC), X represents an oxygen atom, etc., R1 represents a C1-C6 alkyl group, etc., R2 represents a C1-C6 alkyl group, etc., R3 represents an optionally substituted phenyl group, etc., R4 represents a hydrogen atom, etc., and R5 represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.
摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐：（其中Y1表示氮原子或由CRA表示的基团，Y2表示氮原子或由CRB表示的基团，Y3表示氮原子或表示 通过CRC，RA，RB和RC可以相同或不同，各自表示氢原子等（不包括Y1为CRA，Y2为CRB且Y3为CRC的情况），X为氧原子等 R1表示C1-C6烷基等，R2表示C1-C6烷基等，R3表示可以具有取代基的苯基等，R4表示氢原子等，R5表示 任选取代的苯基等）对S1P与其受体Edg-1（S1P1）之间的结合具有抑制作用，并且可用作自身免疫性疾病，类风湿性关节炎，哮喘，特应性皮炎，器官移植后的排斥反应的治疗剂 ，癌症，视网膜病变，牛皮癣，骨关节炎或年龄相关 黄斑变性等
-
搜索结果
12 条记录 (耗时 0.028 秒)